Results 241 to 250 of about 589,804 (355)

Antibody Drug Conjugates for Cancer Therapy

, 2015
Paul Polakis
openalex   +1 more source

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors [PDF]

, 2016
Manisha H. Shah, Paul Lorigan, Mary O’Brien, Frank V. Fossella, Kathleen N. Moore, Shailender Bhatia, Maurice Kirby, Penella J. Woll   +7 more
openalex   +1 more source

Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 × PD-L1 Antibody-Drug Conjugate. [PDF]

Clin Cancer Res
Li C, Yao J, Yang J, Zhang Y, Qiu Y, Zhu Z, Hua H.   +6 more
europepmc   +1 more source

Microbubble‐Controlled Delivery of Biofilm‐Targeting Nanoparticles to Treat MRSA Infection

Advanced Functional Materials, EarlyView.
Here, an effective strategy using microbubble (MB)‐controlled delivery of biofilm‐targeting nanoparticles (BTNs) for removal and therapy of methicillin‐resistant Staphylococcus aureus (MRSA) biofilm infections is introduced. In vivo delivery of MB with BTN is demonstrated to silence key bacterial genes involved in biofilm formation (icaA), bacterial ...
Ju Yeon Chung, Yujin Ahn, Joo Hun Lee, Seungju Yang, Seung Cheol Lee, Hyunjoon Kong, Hyun Jung Chung   +6 more
wiley   +1 more source

Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes [PDF]

, 2016
Yang Feng, Yanping Wang, Zhongyu Zhu, Wei Li, Robyn T. Sussman, Michael P. Randall, Kristopher R. Bosse, John M. Maris, Dimiter S. Dimitrov   +8 more
openalex   +1 more source

Antibody‐Programmable Bimetallic Nanozymes for Transcriptional Blockade Therapy in HER2/ER‐Positive Breast Cancer

Advanced Functional Materials, EarlyView.
Zr‐Fe MOF@Ribociclib@Herceptin (ZFRH) efficiently targets/kills Human Epidermal Growth Factor Receptor 2/Estrogen Receptor‐positive (HER2/ER+) breast cancer cells. It combats tumors by: 1) Elevating ROS, altering redox balance; 2) Inhibiting transcription; 3) Inducing pyroptosis.
Hongkun Miao, Tong Ye, Mingjiang Liu, Jingchao Gao, Lian Tan, Qian Dong, Qingbo Lv, Qianqian Ye, Yu Wang   +8 more
wiley   +1 more source

Typical Antibody–Drug Conjugates [PDF]

, 2016
John M. Lambert
openalex   +1 more source

Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation. [PDF]

CPT Pharmacometrics Syst Pharmacol
Zunino C, Wang S, Zhang Y, Urdy S, de Witte WEA, Declèves X, Puszkiel A, Djebli N.   +7 more
europepmc   +1 more source

Tunable Synthetic Hydrogel Modulates Hepatic Lineage Specification of Human Liver Organoid

Advanced Functional Materials, EarlyView.
In this study, a synthetic hydrogel is reported that supports the formation of hiPSC‐derived human liver organoids (HLOs). Hepatic lineage specification can be modulated via conjugation of RGD peptide to hydrogel: RGD‐conjugated hydrogels promote cholangiocyte differentiation, whereas RGD‐free hydrogels favor hepatocyte commitment of HLO cells.
Lei Wang, Lasse Riediger, Qi Rao, Xun Xu, Yan Nie, Yiduo Zhou, Junyao Zhang, Peng Tang, Weiwei Wang, Frank Tacke, Adrien Guillot, Ludovic Vallier, Irene Talon, Wenzhong Li, Yi‐An Yang, Rainer Haag, Nan Ma   +16 more
wiley   +1 more source

Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease. [PDF]

Oncologist
Zhang S, Zhou J, Zhao X, Gan H, Peng W, Li W, Sun M, Hu J, Yan W.   +8 more
europepmc   +1 more source